CHF73.90
1.79% today
SIX Swiss Exchange, Feb 28, 05:30 pm CET
ISIN
CH0386200239
Symbol
MED
Sector

Medartis Target price 2025 - Analyst rating & recommendation

Medartis Classifications & Recommendation:

Buy
75%
Hold
25%

Medartis Price Target

Target Price CHF89.20
Price CHF73.90
Potential
Number of Estimates 2
2 Analysts have issued a price target Medartis 2026 . The average Medartis target price is CHF89.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 4 analysts: 3 Analysts recommend Medartis to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Medartis stock has an average upside potential 2026 of . Most analysts recommend the Medartis stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Million CHF 212.01 236.85
15.97% 11.72%
EBITDA Margin 15.30% 15.47%
72.25% 1.10%
Net Margin 0.32% 4.90%
108.80% 1,429.97%

4 Analysts have issued a sales forecast Medartis 2024 . The average Medartis sales estimate is

CHF237m
Unlock
. This is
7.52% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF241m 9.41%
Unlock
, the lowest is
CHF228m 3.32%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 CHF212m 15.97%
2024
CHF237m 11.72%
Unlock
2025
CHF271m 14.62%
Unlock
2026
CHF320m 18.03%
Unlock
2027
CHF359m 12.10%
Unlock
2028
CHF400m 11.36%
Unlock

4 Analysts have issued an Medartis EBITDA forecast 2024. The average Medartis EBITDA estimate is

CHF36.6m
Unlock
. This is
41.33% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF39.8m 53.64%
Unlock
, the lowest is
CHF34.4m 32.79%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 CHF32.4m 99.75%
2024
CHF36.6m 12.97%
Unlock
2025
CHF44.4m 21.25%
Unlock
2026
CHF44.0m 1.05%
Unlock
2027
CHF63.5m 44.33%
Unlock
2028
CHF76.0m 19.75%
Unlock

EBITDA Margin

2023 15.30% 72.25%
2024
15.47% 1.10%
Unlock
2025
16.37% 5.82%
Unlock
2026
13.72% 16.19%
Unlock
2027
17.67% 28.79%
Unlock
2028
19.00% 7.53%
Unlock

3 Medartis Analysts have issued a net profit forecast 2024. The average Medartis net profit estimate is

CHF11.6m
Unlock
. This is
176.02% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF14.3m 238.73%
Unlock
, the lowest is
CHF9.5m 125.90%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 CHF679k 110.20%
2024
CHF11.6m 1,611.34%
Unlock
2025
CHF16.9m 45.27%
Unlock
2026
CHF24.2m 43.19%
Unlock
2027
CHF36.3m 50.23%
Unlock

Net Margin

2023 0.32% 108.80%
2024
4.90% 1,429.97%
Unlock
2025
6.22% 26.94%
Unlock
2026
7.54% 21.22%
Unlock
2027
10.11% 34.08%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share CHF 0.05 0.86
110.20% 1,620.00%
P/E 84.87
EV/Sales 4.15

3 Analysts have issued a Medartis forecast for earnings per share. The average Medartis <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

CHF0.86
Unlock
. This is
177.42% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
CHF1.05 238.71%
Unlock
, the lowest is
CHF0.70 125.81%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 CHF0.05 110.20%
2024
CHF0.86 1,620.00%
Unlock
2025
CHF1.24 44.19%
Unlock
2026
CHF1.78 43.55%
Unlock
2027
CHF2.67 50.00%
Unlock

P/E ratio

Current 235.18 84.67%
2024
84.87 63.91%
Unlock
2025
58.42 31.17%
Unlock
2026
40.78 30.20%
Unlock
2027
27.15 33.42%
Unlock

Based on analysts' sales estimates for 2024, the Medartis stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.46 0.68%
2024
4.15 7.05%
Unlock
2025
3.62 12.75%
Unlock
2026
3.06 15.28%
Unlock
2027
2.73 10.79%
Unlock
2028
2.45 10.20%
Unlock

P/S ratio

Current 4.48 2.90%
2024
4.17 7.00%
Unlock
2025
3.64 12.75%
Unlock
2026
3.08 15.28%
Unlock
2027
2.75 10.79%
Unlock
2028
2.47 10.20%
Unlock

Current Medartis Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
RESEARCH PARTNERS AG Locked ➜ Locked Locked Aug 20 2024
BRYAN GARNIER Locked ➜ Locked Locked Aug 19 2024
STIFEL EUROPE Locked ➜ Locked Locked Aug 19 2024
Analyst Rating Date
Locked
RESEARCH PARTNERS AG: Locked ➜ Locked
Aug 20 2024
Locked
BRYAN GARNIER: Locked ➜ Locked
Aug 19 2024
Locked
STIFEL EUROPE: Locked ➜ Locked
Aug 19 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today